(NYSE Amex: DXR) Daxor Announces Filing of Two Additional Patents for Updated Automated Blood Analyzer

NEW YORK, NY--(Marketwire - Mar 9, 2012) - Daxor Corporation (NYSE Amex: DXR), a medical instrumentation and biotechnology company, today announced the filing of two additional patents for an automated instrument to measure human blood volume. These filings describe innovations to be incorporated into the company's BVA-100 Blood Volume Analyzer. These applications supplement the patent application filed 10/25/11 describing a Total Body Albumin Analyzer.

Key innovations described in these two new patent application filed 3/9/12 include:

• An automated quality control module, which improves accuracy and ease of use for the instrument. It ensures that the isotopic counter is optimally calibrated with minimal operator intervention. This uses:
• An integrated peak-search method for channel determination
• An automated linearity adjustment using external stable isotopic standards
• An automated standards / background / linearity check
• An injectate verification system, using bar-coding to insure consistency between standards and patient samples
• A logging database for quality control checks
• A remote diagnostic system for the instrument, allowing for remote verification of accuracy of instrument, and user support; including
• Trend analysis of machine results
• Full spectrum capture and analysis
• Full system logging
• Full usage logging
• A new protocol for measuring blood volume in amputee patients.
• A new protocol for measurement of radio-hematocrit, which measure the proportion of red cells in the blood using the radio-labeled plasma component. This provides for more accurate measurements than the traditional centrifuge method, and also eliminates the need for this extra step outside using the BVA-100.
• A Bad Points Removal Algorithm, that allows for automated detection and removal of bad points in the Blood Volume calculation that may have arisen from errors in an individual sample collection or preparation. A blood volume measurement uses multiple patient samples (typically five), and this algorithm allows for an accurate and precise measurement of blood volume to be obtained, even if a single point is invalid. This protocol features a three-part statistical method for identifying suspect points.

The company expects to be filing an additional patent in the near future relating to a collection system for collecting multiple blood samples from a patient utilizing a method that requires only a single veni-puncture instead of multiple needle sticks.

The inventors on the patent applications are Dr. Joseph Feldschuh and Jonathan Feldschuh. The patents have been assigned to the Daxor Corporation.

For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website at www.Daxor.com.